Injection preparation and preparation method therefor, and compatible medicinal liquid and preparation method therefor
By using a combination of nonionic surfactant and co-solvent in the injection preparation of Compound A, the problem of compound A being inconveniently soluble in ethanol-propanediol mixed solvents was solved, and the stable dissolution and efficient stability of Compound A were achieved. in clinical trials and commercial production of cancer treatment.
Patent Information
- Application Number
- PCT/CN2024/092639
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-14
AI Technical Summary
Compound A is not easily soluble in existing ethanol-propanediol mixed solvents, making it difficult to develop stable injection preparations, affecting its clinical trials and commercial production for cancer treatment.
The combination of nonionic surfactants such as polyoxyethylene (35) castor oil and cosolvents such as N,N-dimethylacetamide and ethanol is used to improve the solubility and stability of Compound A to form a suitable injection preparation prescription. And enhance its stability through specific compatibility media and antioxidants.
The stable dissolution and long-term stability of Compound A are achieved, meeting the requirements of clinical trials and commercial production, and providing an injection preparation suitable for Compound A, which maintains high efficiency stability and solubility under different conditions.
Smart Images

Figure CN2024092639_14112024_PF_FP_ABST
Abstract
Description
Injection preparation, combined medicinal solution and preparation method thereof Technical Field
[0001] The present invention relates to the research and development of an injection of compound No. 16 disclosed in patent application PCT / CN2020 / 089692 (publication number WO2020228685A9), which belongs to the field of formulation development of compounds for cancer treatment. Background Art
[0002] The compound No. 16 disclosed in the applicant's patent application PCT / CN2020 / 089692 (publication number WO2020228685A9) and the compound A disclosed in the patent application PCT / CN2021 / 129077 (publication number WO2023077452A1) are the same compound, and its structural formula is shown in Formula I (hereinafter referred to as Compound A). After further research, it was found that the compound of Formula I has excellent anticancer efficacy, toxic side effects, safety and stability, especially in tumor tissues or cells that overexpress aldo-keto reductase 1C3 (AKR1C3). It can be targeted for identification and targeted treatment, and can enter the brain or other central nervous systems to exert its efficacy. The Chinese name of the compound of Formula I (Compound A) is 1-(3-((2,4'-difluoro-[1,1'-biphenyl]-4-yl)oxy)-4-nitrophenyl)-2,2,2-trifluoroethyl-bis(aziridine-1-yl) phosphate, and its structure is shown in the following formula:
[0003] To conduct subsequent clinical trials, a suitable dosage form must be prepared for patient administration, typically oral or parenteral. Therefore, a pharmaceutical formulation for Compound A (Formula I, also referred to herein as the API) is needed for the treatment of cancer patients overexpressing aldehyde-keto reductase 1C3 (AKR1C3).
[0004] The applicant disclosed in patent application PCT / CN2020 / 101870 (publication number WO2021008520A1, corresponding to Chinese patent application CN202080001484.5, publication number CN112469394A) the prescription and preparation method of an injection preparation of compound AST-3424, which has a structure similar to compound A. Compound AST-3424 and compound A are both nitrobenzyl derivatives, and are both connected to DNA alkylating agents with an aziridine structure that can effectively kill tumor cells. They can also target and treat tumor tissues or cells that overexpress aldehyde-keto reductase 1C3 (AKR1C3), and release DNA alkylating agents with an aziridine structure in tumor tissues or cells that overexpress the AKR1C3 enzyme to achieve the purpose of killing tumor tissues or cells.
[0005] Therefore, based on the same formulation formulation development idea, the inventors designed and screened an injection formulation similar to compound AST-3424 for use in the formulation research of compound A.
[0006] Summary of the Invention
[0007] The inventors discovered that Compound A was poorly soluble in the ethanol-propylene glycol mixed solvent used as the formulation solvent for Compound AST-3424. The approach of researching and screening liquid formulations for Compound A using a formulation similar to AST-3424 was unworkable. Therefore, the inventors conducted further research and developed the following stable formulation suitable for Compound A and its preparation method.
[0008] The present invention provides an injection formulation of Compound A, its preparation method, and a compatible solution and its preparation method. The injection formulation provided by the technical solutions of the present invention has been verified to meet the requirements of long-term clinical trials and commercial production and sales. Specifically, this application discloses a series of technical solutions for the injection of Compound A.
[0009] The present invention provides an injection preparation of Compound A, which is a solution containing the compound of Formula I:
[0010] The solution is a storage-stable concentrated form of compound A injection preparation, which needs to be diluted before administration. Medical personnel, pharmacists, pharmacies or factories need to dilute or prepare it as required when it is used to obtain a ready-to-use injection.
[0011] The concentrated injection of the present invention can be diluted with a solution prepared by using any medically acceptable isotonicity-adjusting agent (as a solute) and water for injection (as a solvent).
[0012] Suitable isotonicity adjusting agents include, but are not limited to, anhydrous or aqueous sodium chloride, glucose, sucrose, fructose, xylitol, glycerol, sorbitol, mannitol, potassium chloride, mannose, calcium chloride, magnesium chloride and other inorganic salts. Preferably, the isotonicity adjusting agent is glucose or sodium chloride.
[0013] In the injection preparation solution of compound A provided by the present invention, the solvent of the solution contains a C2-C8 alcohol or a liquid mixture thereof.
[0014] C2-C8 alcohols, including straight-chain, branched-chain, and cyclic aliphatic alcohols and aromatic alcohols, but excluding phenols and the more active benzyl alcohol.
[0015] Specifically, the C2-C8 alcohol is a monohydric alcohol or a polyhydric alcohol, and the polyhydric alcohol is a dihydric alcohol, a trihydric alcohol or a hexahydric alcohol. Preferably, the C2-C8 alcohol is a monohydric alcohol, and more preferably, it is ethanol.
[0016] Furthermore, the C2-C8 alcohol includes C2-C4 monohydric alcohol, C2-C6 dihydric alcohol and C3-C6 trihydric alcohol. Therefore, the solvent of the above-mentioned injection preparation solution can be a liquid mixed solvent of C2-C4 monohydric alcohol and C2-C6 dihydric alcohol, or a liquid mixed solvent of C2-C4 monohydric alcohol and C3-C6 trihydric alcohol.
[0017] Obviously, the mixed solvent of C2-C8 monohydric alcohol and C2-C8 dihydric alcohol, trihydric alcohol or hexahydric alcohol defined in the present invention means that the above-mentioned monohydric alcohol and dihydric alcohol, trihydric alcohol or hexahydric alcohol should each be liquid at room temperature and pressure, or the mixed solvent after mixing should be liquid.
[0018] Furthermore, the dihydric alcohol includes ethylene glycol and propylene glycol, the trihydric alcohol includes glycerol, and the hexahydric alcohol includes mannitol or sorbitol.
[0019] In the injectable formulation of Compound A provided herein, the monohydric alcohol contained in the solvent of the solution is preferably ethanol. Ethanol, as a solvent or carrier for the active pharmaceutical ingredient Compound A in the injectable formulation, is commonly used in medicine as a solvent for injectables. However, the inventors have discovered through experiments that the solubility of the active pharmaceutical ingredient Compound A in ethanol alone or in a mixed solvent of ethanol and the aforementioned polyols is low. Therefore, a specific surfactant is required as a cosolvent or solubilizing agent to increase the solubility of Compound A in the solvent system and even enhance its stability.
[0020] The solution of the injection preparation of Compound A provided by the present invention contains, in addition to a C2-C8 alcohol or a liquid mixture thereof, at least one surfactant, particularly a nonionic surfactant, which has a solubilizing effect.
[0021] Preferably, the solvent of the solution contains, in addition to the C2-C8 alcohol or its liquid mixture, a nonionic surfactant as a solubilizer.
[0022] The process of increasing the solubility of poorly soluble drugs by adding surfactants is called solubilization, and the added surfactant is a solubilizing agent.
[0023] Surfactants are substances that can significantly reduce the surface tension of a target solution. They generally have fixed hydrophilic and lipophilic groups that can be arranged in a directional manner on the surface of the solution. The molecular structure of a surfactant is amphiphilic: one end is a hydrophilic group, and the other end is a hydrophobic group. The hydrophilic group is often a polar group, such as carboxylic acid, sulfonic acid, sulfuric acid, amino or amine groups and their salts. Hydroxyl groups, amide groups, ether bonds, etc. can also serve as polar hydrophilic groups. The hydrophobic group is often a non-polar hydrocarbon chain, such as a hydrocarbon chain with more than 8 carbon atoms. Surfactants are divided into nonionic surfactants and ionic surfactants based on whether the surfactant molecule contains an undissociated ether group as the main hydrophilic group in the aqueous solution.
[0024] Nonionic surfactants refer to surfactants that do not dissociate in water, including but not limited to ester-type surfactants, span-type surfactants, ether-type surfactants, peregal-type surfactants, amine-type surfactants, amide-type surfactants, Tween-type surfactants, and ester-ether-type surfactants.
[0025] The non-ionic surfactant can be polyethylene glycol (PEG) with -O-CH2-CH2- as the repeating unit, such as polyethylene glycol 200 (PEG200), polyethylene glycol 400 (PEG400), polyethylene glycol 600 (PEG600), polyethylene glycol 800 (PEG800), etc. Among them, PEG400 is a liquid. It has wide compatibility with various solvents, is a good solvent and solubilizer, and is widely used in liquid preparations.
[0026] Nonionic surfactants can also be surfactants with polyethylene glycol (or polyoxyethylene) segments as the hydrophilic part. Polyethylene glycol has relatively low toxicity and can be smoothly metabolized in the body. Its simple ethylene oxide repeating unit makes it all have good solubility in organic solvents and aqueous solutions. After different hydrophobic substances are connected to the polyethylene glycol segments, different active agent types are formed, and the changes in the polyethylene glycol (PEG) chain (segment length, number of segments, connection position, etc.) can further enrich the optional varieties of nonionic surfactants.
[0027] Furthermore, the nonionic surfactant of the present invention can be selected from polyethylene glycols, hydroxystearates, polyoxyethylene alkyl ethers, Tweens, Spans, or polyoxyethylene castor oils. Of course, a mixture of two or more of the above surfactants can also be selected, as long as the mixture can still significantly reduce the surface tension of the target solution. The nonionic surfactant provided by the present invention can solubilize insoluble substances and has the effect of a solubilizing agent.
[0028] Hydroxystearic acid polyethylene glycol esters, including 15-hydroxystearic acid polyethylene glycol ester (HS15) and 12-hydroxystearic acid polyethylene glycol ester (HS12), can be obtained by dehydrating and condensing polyethylene glycol single chains containing different ethylene oxide repeating units with hydroxystearic acid to form esters. These esters are commonly used as excipients for lipophilic drugs in preparations, mainly as non-ionic solubilizers.
[0029] By connecting polyethylene glycol single chains of different molecular weights to simple fatty alkyl long chains, polyethylene glycol alkyl ethers (Polyoxyethylene Alkyl Ethers) can be obtained, including lauryl ether alkyl, oleyl ether alkyl, stearyl alcohol alkyl, hexadecyl, etc., which can be used as solubilizers in formulations. Polyethylene glycol alkyl ethers that can be used as solubilizers are all optional options for the nonionic surfactants of this application. As shown in the following polyoxyethylene alkyl ether structural formulas B and C, different polyoxyethylene alkyl ethers can be obtained when n takes different values and R is a different group.
[0030] With sorbitan as the core structure, four polyethylene glycol (PEG) segments are attached to the central unit at one end. One of the PEG segments is terminated by a long fatty chain, as shown in Formula D below. This forms the general structure of a Tween-like surfactant. Common Tween grades include Tween 20, Tween 40, Tween 60, and Tween 80. In these surfactants, the total number of PEG repeating units is 20 (w+x+y+z=20). The different fatty acid chains attached to the PEG ends can include lauric acid, palmitic acid, stearic acid, and oleic acid.
[0031] By removing or replacing the PEG segments in the Tween structure with long fatty chains, another type of surfactant, Span, can be obtained, which is a type of water-insoluble surfactant.
[0032] Castor oil, also known as glycerol ricinoleate, reacts with ethylene oxide, and the hydrophilic ethylene oxide structure is inserted between ricinoleic acid and glycerol to obtain polyoxyethylene castor oil. If the double bonds in castor oil are hydrogenated and saturated, and then reacted with ethylene oxide, the result is polyoxyethylene hydrogenated castor oil. Those skilled in the art should know that the reaction sites of ethylene oxide and castor oil are random, so the surfactant obtained is a mixture, which also includes unreacted castor oil and polyoxyethylene formed by homopolymerization. Different types of polyoxyethylene castor oil or polyoxyethylene hydrogenated castor oil are determined by the ratio of ethylene oxide and castor oil or hydrogenated castor oil involved in the reaction. For example, polyoxyethylene (35) castor oil (hereinafter referred to as ELP) can be obtained by reacting 1 mol of castor oil with 35 mol of ethylene oxide.
[0033] In particular, in the technical solution of the present invention containing surfactants, polyethylene glycols include PEG200, PEG400, PEG600, PEG800, etc.; hydroxystearate includes HS12, HS15, etc.; alkyl groups in polyoxyethylene alkyl ether include lauryl ether alkyl, oleyl ether alkyl, stearyl alcohol alkyl, hexadecyl, etc.; Tweens include Tween 20, Tween 40, Tween 60, Tween 80, etc.; Span includes Span 20, Span 40, Span 60, Span 80, etc.; polyoxyethylene castor oils include polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, etc.
[0034] Furthermore, the polyoxyethylene castor oil of the present invention may be polyoxyethylene (35) castor oil. The pharmaceutically acceptable polyoxyethylene (35) castor oil is polyoxyethylene glycerol triricinoleate, which may also contain a small amount of polyethylene glycol ricinoleate and free ethylene glycol, and its ethylene glycol content does not exceed 620 ppm. It can be obtained by reacting 1 mol of castor oil with 35 mol of ethylene oxide. According to the gel method measurement of 1143 of the fourth part of the Chinese Pharmacopoeia 2015 edition, the bacterial endotoxin content in each 1 mg of polyoxyethylene (35) castor oil does not exceed 0.012 EU.
[0035] Preferably, in the injection preparation solution of compound A provided by the present invention, the solvent of the solution contains, in addition to C2-C8 alcohol or its liquid mixture, one or more of polyoxyethylene (35) castor oil, 15-hydroxystearate polyethylene glycol ester, polyethylene glycol 400, and Tween 80.
[0036] In the above injection preparation solution containing a surfactant, the volume ratio of the surfactant to the C2-C8 alcohol is 1:(1-4), and in particular, the surfactant is selected from a nonionic surfactant.
[0037] In particular, when the surfactant is ELP and the C2-C8 alcohol is ethanol, the volume ratio of ELP to ethanol is 1:3;
[0038] When the surfactant is HS15 and the C2-C8 alcohol is ethanol, the volume ratio of HS15 to ethanol is 1:4;
[0039] When the surfactant is PEG400 and the C2-C8 alcohol is ethanol, the volume ratio of PEG400 to ethanol is 1:1;
[0040] When the surfactant is Tween 80 and the C2-C8 alcohol is ethanol, the volume ratio of Tween 80 to ethanol is 1:1.
[0041] In another solution of an injection preparation of Compound A provided by the present invention, the solvent of the solution contains, in addition to C2-C8 alcohol or a liquid mixture thereof, an organic solvent with a solubilizing effect.
[0042] This organic solvent is called a cosolvent. The poorly soluble drug and the added third substance form a soluble complex (complex, associate, or double salt) in the solvent, increasing the solubility of the drug. The added third substance is also called a cosolvent. Cosolvents include: ① organic acids and their salts, such as sodium benzoate, potassium iodide, sodium salicylate, and para-aminobenzoic acid; ② amide or amine compounds, such as ethylenediamine, urethane, urea, N,N-dimethylacetamide (DMA), or N,N-dimethylformamide; and ③ water-soluble polymers, such as polyvinylpyrrolidone.
[0043] Preferably, in the technical solution of the present invention containing a co-solvent, the co-solvent is selected from ethylenediamine, N,N-dimethylacetamide, N,N-dimethylformamide or polyvinylpyrrolidone, more preferably N,N-dimethylacetamide.
[0044] Pharmaceutically acceptable N,N-dimethylacetamide (DMA) should be of injectable grade with a purity of not less than 99.8%, according to USP general principles. <85> The bacterial endotoxin content in each 1 ml of N,N-dimethylacetamide was not more than 2.0 EU as determined by gel electrophoresis.
[0045] In the above-mentioned injection preparation solution containing a cosolvent, the mass ratio of the organic solvent with a cosolvent effect to compound A in the solvent of the solution is (10-50):1.
[0046] In the injection preparation of compound A provided by the present invention, the solvent of the solution contains, in addition to C2-C8 alcohol or its liquid mixture, a nonionic surfactant as a solubilizer and an organic solvent for solubilization.
[0047] Preferably, the nonionic surfactant is selected from polyoxyethylene (35) castor oil, and the organic solvent with solubilizing effect is selected from N,N-dimethylacetamide.
[0048] In particular, the mass ratio of the nonionic surfactant to compound A in the solvent of the solution is (0-90):1, preferably (5-50):1, more preferably (15-40):1, more preferably (20-40):1, and further preferably (25-40):1;
[0049] The mass ratio of the organic solvent having a solubilizing effect to compound A in the solvent of the solution is (0-100):1, preferably (1-50):1, more preferably (5-25):1, and further preferably (5-10):1.
[0050] The injection preparations of Compound A provided by the present invention include injection preparations in various solvents mentioned above, wherein the solvents are selected from:
[0051] (1) C2-C8 alcohols,
[0052] (2) a combination of a C2-C8 alcohol and a solubilizing nonionic surfactant,
[0053] (3) a combination of a C2-C8 alcohol and a solubilizing organic solvent, or
[0054] (4) A combination of a C2-C8 alcohol, a solubilizing nonionic surfactant, and an organic solvent with a solubilizing effect.
[0055] As a preferred injection preparation provided by the present invention, the content of compound A is 0.1-200 mg / ml, preferably 1-100 mg / ml, and more preferably 10-20 mg / ml.
[0056] Taking into account various factors such as stability and ease of use, the injection preparation of Compound A provided by the present invention is a solution containing 10 mg / ml of Compound A. This concentration is the recommended value by the research and development team, and it has shown relatively good properties in experimental comparisons.
[0057] The present invention provides an injection preparation containing compound A, N,N-dimethylacetamide, polyoxyethylene (35) castor oil and ethanol.
[0058] The present invention provides an injection preparation, which is composed of a compound of the following formula I, N,N-dimethylacetamide, polyoxyethylene (35) castor oil and ethanol:
[0059] As a preferred embodiment of the present invention, the content of the compound of formula I is 0.1-200 mg / ml, preferably 1-100 mg / ml, more preferably 10-20 mg / ml, and even more preferably 10 mg / ml.
[0060] As a preferred embodiment of the present invention, the mass ratio of the compound of formula I to N,N-dimethylacetamide is 1:(0-100), preferably 1:(1-50), more preferably 1:(5-25), further preferably 1:(5-10), and even more preferably 1:5.
[0061] As a preferred embodiment of the present invention, the mass ratio of the compound of formula I to polyoxyethylene (35) castor oil is 1:(0-90), preferably 1:(5-50), more preferably 1:(15-40), further preferably 1:(20-40), further preferably 1:(25-40), and even more preferably 1:40.
[0062] The present invention provides an injection preparation, which is a 2 ml ethanol solution containing 20 mg of compound A (Formula I), 100 mg of N,N-dimethylacetamide and 800 mg of polyoxyethylene (35) castor oil.
[0063] The present invention provides a unit injection preparation, which is a concentrated ethanol solution, marked as having a volume of 2 ml, containing 20 mg of compound A, 100 mg of N,N-dimethylacetamide and 800 mg of polyoxyethylene (35) castor oil.
[0064] Unit injection preparation refers to a unit packaged preparation that is ultimately sold in a packaging container such as a vial or ampoule, which is an ethanol concentrated solution. In addition to containing the drug compound A, it also contains the auxiliary solvent ethanol, cosolvent DMA, and solubilizer ELP. The specification on the label of the unit preparation is recorded as 2ml:20mg, that is, 2ml of the unit injection preparation (i.e., ethanol concentrated solution) contains 20mg of drug compound A, 100mg of N,N-dimethylacetamide, and 800mg of polyoxyethylene (35) castor oil (the rest is solvent ethanol). The specifications here of 2ml:20mg drug compound A:100mg of N,N-dimethylacetamide:800mg of polyoxyethylene (35) castor oil are all labeled values and are also the calculated values when the prescription is added. The actual measured values may have certain deviations.
[0065] In order to further enhance the stability of the injection preparation against time and heat, other substances that are harmless and do not react with Compound A may be added. Generally speaking, these substances include:
[0066] Protective gas is a process of greatly reducing the content of certain active gases such as O2 and CO2 in the injection solution by evacuating the injection solution, and then filling it with inert gas that does not react with the raw material drug, monohydric alcohol, dihydric alcohol, trihydric alcohol, hexahydric alcohol, N,N-dimethylacetamide, N,N-dimethylformamide or surfactant (such as polyoxyethylene (35) castor oil, HS15, Tween 80, etc.), such as N2 or other inert gases. These protective gases will dissolve in the injection solution or fill in the packaging container.
[0067] Antioxidants: Stability can be further improved by adding an appropriate amount of antioxidants (such as butylated hydroxyanisole (BHA), 2,6-di-tert-butylated hydroxytoluene (BHT), vitamin E (tocopherol), vitamin C or glutathione) to the injection solution.
[0068] In order to improve patient compliance, correspondingly, anesthetic or analgesic drugs in doses permitted by the pharmacopoeia or formulary may be added.
[0069] The injection disclosed in the present invention may also contain another therapeutic agent to form a compound preparation to exert a synergistic effect and enhance the therapeutic effect. In particular, these drugs are recommended to be drugs that regulate the AKR1C3 enzyme content or the corresponding gene expression level.
[0070] In some cases, in order to cope with special environments, the injection disclosed in the present invention may also be added with antibacterial agents and antifungal agents.
[0071] In addition, electrolytes such as salts NaCl and KCl, and substances such as glucose and amino acids that regulate acid-base balance and osmotic pressure, which are often used in injection solutions, can also be added according to the situation.
[0072] Obviously, the added amounts of the above protective gases, antioxidants, anesthetic or analgesic drugs, antibacterial agents, antifungal agents, etc. are very small, and they do not affect the solubility and other properties of the Compound A API or can enhance the stability; while the content of another therapeutic agent, acid-base balance regulating and osmotic pressure regulating substance needs to be added according to the actual situation such as purpose, prescription amount, pharmacopoeia, formulary, etc.
[0073] The injection preparation of Compound A provided by the present invention does not contain water, and the mass content of water is less than or equal to 1.0%, preferably less than or equal to 0.5%.
[0074] Obviously, not adding water means that no additional water is added during the preparation process, and other reagents, solvents, etc. used are anhydrous grade reagents, such as anhydrous ethanol, anhydrous propylene glycol, anhydrous polyoxyethylene (35) castor oil, anhydrous N, N-dimethylacetamide, etc., that is, the injection of the present invention needs to control the water content during the preparation process. In theory, the lower the water content of the injection, the better the stability. However, considering the technical difficulty and the reality of industrial mass production, the research and development team decided that the water content (determined by Karl Fischer method) should be within 1.0% by mass, preferably not more than 0.5%.
[0075] The inventors' team found through research that the solubility of compound A in ethanol, polyoxyethylene (35) castor oil and N,N-dimethylacetamide gradually increases, that is, the solubility of compound A in ethanol is relatively the lowest and in N,N-dimethylacetamide is relatively the highest. Therefore, the present invention also provides the following injection preparation technical solution:
[0076] i. An injection preparation comprising compound A and polyoxyethylene (35) castor oil, and optionally ethanol.
[0077] ii. An injection preparation comprising Compound A and N,N-dimethylacetamide, and optionally ethanol.
[0078] iii. An injection preparation comprising compound A, polyoxyethylene (35) castor oil and N,N-dimethylacetamide, but excluding ethanol.
[0079] Obviously, when ethanol is not contained, injection preparation i is a solution with polyoxyethylene (35) castor oil as a solvent, injection preparation ii is a solution with N,N-dimethylacetamide as a solvent, and injection preparation iii can be considered as a solution with N,N-dimethylacetamide as a solvent. Those skilled in the art should know that the above-mentioned injection preparations i, ii, and iii are injection solutions in liquid form with Compound A as the raw material.
[0080] Of course, in order to further enhance the time and heat stability of the injection preparations i, ii and iii or improve patient compliance, other substances that are harmless and do not react with compound A may be added, such as the protective gas, antioxidants and anesthetic or analgesic drugs mentioned above.
[0081] The injections i, ii, and iii disclosed in the present invention may also contain another therapeutic agent to form a compound preparation to exert a synergistic effect and enhance the therapeutic effect. In particular, these drugs are recommended to be drugs that regulate the AKR1C3 enzyme content or the corresponding gene expression level.
[0082] In some cases, in order to cope with special environments, the injections i, ii and iii disclosed in the present invention may also be added with antibacterial agents and antifungal agents.
[0083] In addition, electrolytes such as salts NaCl and KCl, and substances such as glucose and amino acids that regulate acid-base balance and osmotic pressure, which are often used in injection solutions, can also be added according to the situation.
[0084] Obviously, the added amounts of the above protective gases, antioxidants, anesthetic or analgesic drugs, antibacterial agents, antifungal agents, etc. are very small, and they do not affect the solubility and other properties of the Compound A API or can enhance the stability; while the content of another therapeutic agent, acid-base balance regulating and osmotic pressure regulating substance needs to be added according to the actual situation such as purpose, prescription amount, pharmacopoeia, formulary, etc.
[0085] The injection preparations i, ii and iii provided by the present invention do not contain water, and the mass content of water is less than or equal to 1.0%, preferably less than or equal to 0.5%.
[0086] The present invention provides an injection preparation product, comprising a packaging container and an injection preparation contained in the container, wherein the injection preparation is any one of the injection preparations mentioned above and is filled in a light-proof glass bottle surrounded by a medium borosilicate glass tube, wherein the content of compound A in the injection preparation is 0.1-200 mg / ml, preferably 1-200 mg / ml, and more preferably 10-20 mg / ml.
[0087] The present invention provides an injection preparation product, which is essentially composed of compound A, N,N-dimethylacetamide, polyoxyethylene (35) castor oil and ethanol, and the injection preparation is filled in a light-proof glass bottle with a volume of 2 ml, 5 ml or 10 ml and a medium borosilicate glass tube. In particular, the content of compound A in the injection preparation is 10 mg / ml, the mass ratio of the compound of formula I to N,N-dimethylacetamide is 1:5, and the content of the compound of formula I to polyoxyethylene (35) castor oil is 1:40.
[0088] The above is a specific embodiment of the injection preparation of Compound A, which can be filled in a light-proof glass bottle with a volume of 2 ml, 5 ml or 10 ml and a medium borosilicate glass tube, and then capped with a rubber stopper and sealed with an aluminum-plastic composite cap for an antibiotic bottle. Obviously, the light-proof glass bottle and the rubber stopper are the inner packaging materials that directly contact the injection preparation.
[0089] In particular, the concentration of the raw material compound A of the injection solution of this embodiment will be calibrated to 10 mg / ml, or the concentration of N,N-dimethylacetamide will be calibrated to 50 mg / ml, or the concentration of polyoxyethylene (35) castor oil will be calibrated to 400 mg / ml. In the pharmaceutical standards, the actual tested content will change, and it should be considered as a qualified concentration within the corresponding range of the pharmacopoeia or formulary or pharmaceutical standards. That is to say, the corresponding range concentration in the above standards is technically equivalent to the calibrated concentration.
[0090] Similarly, during the solution preparation or mixing process, the actual volume after mixing is often smaller than the sum of the volumes before mixing. Therefore, in the technical solution provided by the present invention, the reasonable volume changes caused by the preparation or mixing of the solutions are also well known to those skilled in the art (researchers or medical staff in the fields of pharmaceutical research and development, organic chemical synthesis, formulation research and development, etc.).
[0091] The present invention provides a method for preparing an injection preparation, which comprises the following steps: adding a prescribed amount of compound A to a prescribed amount of N,N-dimethylacetamide and stirring to dissolve, then adding a prescribed amount of polyoxyethylene (35) castor oil and stirring to dissolve, and finally adding ethanol to the prescribed volume, mixing and dissolving to obtain the injection preparation.
[0092] Furthermore, the method for preparing the injection preparation is: adding 20 mg of compound A to 100 mg of N,N-dimethylacetamide and stirring to dissolve, then adding 800 mg of polyoxyethylene (35) castor oil and stirring to dissolve, and finally adding ethanol to a volume of 2 ml and mixing and dissolving.
[0093] The present invention also provides another method for preparing an injection preparation, which comprises the following operations: adding a prescribed amount of compound A to a prescribed amount of N,N-dimethylacetamide and stirring to dissolve, thereby obtaining a first dissolving preparation; adding a prescribed amount of polyoxyethylene (35) castor oil to a portion of ethanol and stirring to dissolve, thereby obtaining a second dissolving preparation; adding the first dissolving preparation to the second dissolving preparation, stirring until clarified, and then adding ethanol to the prescribed volume, and mixing and dissolving to obtain the preparation.
[0094] This operation step is based on the fact that polyoxyethylene (35) castor oil is relatively viscous below 20° C. Therefore, polyoxyethylene (35) castor oil and part of anhydrous ethanol are first mixed evenly.
[0095] The present invention also provides an injection of compound A, which is a ready-to-use pharmaceutical composition injection. The composition does not need to be diluted before administration and is suitable for administration during production, without the need for medical personnel to dilute or prepare it before use.
[0096] Obviously, the injection solution of compound A can be a ready-to-use injection solution in various ways, such as intradermal, subcutaneous, intramuscular, intravenous injection, etc.
[0097] The following description is made using a ready-to-use intravenous injection solution as an example. Those skilled in the art can also design intradermal, subcutaneous, intramuscular (muscular) injections, etc. according to clinical needs.
[0098] The instant injection of compound A provided by the present invention is prepared from water, an isotonicity adjusting agent, and any one of the above injection preparations. A pH adjuster may or may not be added to the injection.
[0099] pH adjusters, that is, substances that adjust pH, include salts of alkali metals and alkaline earth metals of weak acids such as carbonic acid, phosphoric acid, citric acid, and acetic acid, and inorganic bases such as hydroxides of alkali metals and alkaline earth metals such as Na and K: sodium citrate, potassium citrate, sodium acetate, potassium acetate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, sodium phosphate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, and potassium carbonate.
[0100] The present invention provides an example of a ready-to-use injection solution of compound A, which contains water, an isotonicity adjusting agent, compound A, N,N-dimethylacetamide, polyoxyethylene (35) castor oil, ethanol, and a pH adjuster.
[0101] Obviously, the above-mentioned ready-to-use injection solution is an isotonic solution with a pH value of 6.8-10.5 and a concentration of Compound A of 0.016-1.10 mg / ml.
[0102] Isotonic solutions, for humans, are generally considered isotonic at 308 mmol / L, such as 0.9% saline or 5% glucose solution. However, values between 280-320 mmol / L are also considered isotonic.
[0103] Of course, if the appropriate treatment subject is other animals, such as other primates, the concentration of the isotonic solution will be adjusted accordingly.
[0104] Particularly, the concentration of Compound A is 0.02-1.00 mg / ml.
[0105] In particular, the pH value of the ready-to-use injection solution is 7.4-8.1, preferably 7.7. The injection solution at this pH value has good stability and can ensure that it can be stored for a certain period of time (for example, after on-site preparation, the patient is temporarily unable to take the medicine on time, or during intravenous infusion, the infusion also takes a certain amount of time to complete).
[0106] The pH adjuster in the injection of compound A provided by the present invention, that is, the substance for adjusting pH mentioned above, includes salts of alkali metals and alkaline earth metals of weak acids such as carbonic acid, phosphoric acid, citric acid, and acetic acid, as well as inorganic bases such as hydroxides of alkali metals and alkaline earth metals such as Na and K: sodium citrate, potassium citrate, sodium acetate, potassium acetate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, sodium phosphate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate. Obviously, the pH adjuster in the injection of the present invention can be a single substance mentioned above, or a combination of multiple substances that have a synergistic effect in adjusting pH.
[0107] The isotonicity regulating agent in the ready-to-use injection of Compound A provided by the present invention can be any medically acceptable osmotic pressure regulating agent relative to the injection of the present invention. Suitable osmotic pressure regulating agents include, but are not limited to, anhydrous or aqueous sodium chloride, glucose, sucrose, fructose, xylitol, glycerol, sorbitol, mannitol, potassium chloride, mannose, calcium chloride, magnesium chloride, other inorganic salts, or mixtures thereof.
[0108] The present invention provides a ready-to-use injection of compound A, which is composed of water, an isotonicity regulating agent glucose, compound A, N,N-dimethylacetamide, polyoxyethylene (35) castor oil, ethanol, and a pH regulator sodium bicarbonate. The injection is an isotonic solution with a pH value of 7.4, a concentration of compound A of 0.016-1.10 mg / ml, and a glucose content of 4.5-5.0% by mass.
[0109] Preferably, the concentration of compound A is 0.02-1.00 mg / ml.
[0110] Preferably, the mass ratio of compound A to N,N-dimethylacetamide is 1:5.
[0111] Preferably, the mass ratio of compound A to polyoxyethylene (35) castor oil is 1:40.
[0112] The present invention also provides a method for preparing a ready-to-use intravenous injection of Compound A, comprising the following steps:
[0113] (a) adding an appropriate amount of sodium bicarbonate solution containing a pH adjuster to 5% glucose injection to obtain a mixed solution, such that the pH value of the mixed solution is 7.7-8.1;
[0114] (b) adding any injection preparation described in the present application or any injection preparation in any injection preparation product described in the present application to the mixed solution of (a) and mixing and dissolving to obtain the product.
[0115] Preferably, in step (a), the mixed solution is obtained by adding 1 volume of 5% sodium bicarbonate injection to 250 volumes of 5% glucose injection.
[0116] In a specific embodiment, the amount and concentration of the pH regulator sodium bicarbonate solution, the amount of 5% glucose injection, and the amount of Compound A injection preparation are calculated. BRIEF DESCRIPTION OF THE DRAWINGS
[0117] FIG1 is a flow chart of the production process of a concentrated injection preparation of Compound A. DETAILED DESCRIPTION
[0118] The non-ready-to-use concentrated injection, its packaged product and injection (ready-to-use pharmaceutical composition injection) provided by the present invention meet the storage stability requirements of the compound of formula I (Compound A).
[0119] In certain embodiments, the concentrated injection provided by the present invention, under long-term stability test conditions (-20°C ± 5°C) for 6 months, the results of various items (properties, pH value, moisture, related substances, content) showed stable trends, no significant changes, and all met the proposed quality standards.
[0120] In certain embodiments, the concentrated injection provided by the present invention, under accelerated stability test conditions (5°C ± 3°C) for 6 months, the results of single impurities and total impurities all meet the standard requirements; the results of other items (properties, pH value, moisture, content) are stable and do not show obvious changes, all meeting the proposed standard requirements.
[0121] In certain embodiments, the concentrated injection provided by the present invention is placed under high temperature (25°C ± 2°C) and light conditions for 30 days and placed under two freeze-thaw conditions for 3 cycles, and there is no obvious change in appearance, and all are light yellow clear liquids.
[0122] In certain embodiments, the concentrated injection provided by the present invention is placed under high temperature (25°C ± 2°C) and light conditions for 30 days and placed under two freeze-thaw conditions for 3 cycles, and the pH does not change significantly and is within the range of 4.5 to 7.0.
[0123] In certain embodiments, the concentrated injection provided by the present invention is placed at high temperature (25°C ± 2°C) under light conditions for 30 days and placed under two freeze-thaw conditions for 3 cycles, and the visible foreign matter meets the standards.
[0124] In certain embodiments, the concentrated injection provided by the present invention is placed under high temperature (25°C ± 2°C) conditions for 30 days, and the total impurities are lower than the standard 5.0%; when placed under light (with outer packaging, pharmacopoeial illumination, 15°C) and light (without outer packaging, pharmacopoeial illumination, 15°C) conditions for 30 days, the total impurities are lower than the standard 5.0%, and the impurity growth rate under light exposure with and without outer packaging is the same, and the growth rate is lower than that under high temperature (25°C ± 2°C) conditions, both meeting the quality standards.
[0125] In certain embodiments, the concentrated injection provided by the present invention is placed at high temperature (25°C ± 2°C) under light conditions for 30 days and placed under two freeze-thaw conditions for 3 cycles, and the moisture content is no more than 0.3%, which meets the standard.
[0126] In certain embodiments, the concentrated injection provided by the present invention is placed under two freeze-thaw conditions for the third cycle, and no bacteria grows, which meets the standards.
[0127] In certain embodiments, the concentrated injection provided by the present invention has a bacterial endotoxin content of less than 1.2 EU / mg after the third cycle under two freeze-thaw conditions, which meets the standard.
[0128] In certain embodiments, the concentrated injection provided by the present invention is placed under high temperature (25°C ± 2°C) conditions for 30 days, and the content decreases by 3.4%, which meets the quality standard requirements; when placed under light (with outer packaging, pharmacopoeial illumination, 15°C) and light (removing outer packaging, pharmacopoeial illumination, 15°C) conditions for 30 days, and under freeze-thaw 1 (-20°C ± 5°C for 2 days → 5°C ± 3°C for 2 days) and freeze-thaw 2 (-20°C ± 5°C for 2 days → 25°C ± 2°C for 2 days) conditions for 3 cycles, the content did not show obvious fluctuations, and all met the quality standard requirements.
[0129] In certain embodiments, the ready-to-use injection provided by the present invention can be stable in appearance, solution color, solution clarity, pH value, osmotic pressure, related substances, and content for 6 hours or even 8 hours under indoor natural light and room temperature (25±3°C) storage conditions, meeting the requirements of injection clinical trials.
[0130] In certain embodiments, the chirality of Compound A in the concentrated injection and the compatible drug solution provided by the present invention is stable, and chiral conversion between the two isomers is almost non-existent.
[0131] The pH value of instant injection for parenteral administration of the present invention can be regulated with an amount of pH adjusting agent, and pH adjusting agent comprises acid-base group.Suitable pH adjusting agent usually comprises at least a kind of acid or its salt, or at least comprises a kind of alkali or its salt.Add acid-base adjustment to reach the pH value of expectation.For example, if the pH value is lower than the pH value of expectation, then add alkali (or some salt) so that the pH value is raised to the pH value of expectation.
[0132] In certain embodiments, the concentrated injectable solutions of the present invention are sterile, such as by terminal sterilization.
[0133] The composition injection of the present invention is packaged in a medically acceptable container, which can be an intravenous infusion bag or a bottle. The infusion bag and bottle can be made of glass, suitable plastics, or polymers. The entire or a substantial portion of the packaging container can be comprised of the following materials: polyvinyl chloride, polyolefin, polyester, polypropylene, or a combination thereof. In other embodiments, only the surface material that contacts the drug injection contains these materials. A preferred embodiment of the present invention is a vial.
[0134] The concentrated injection of the present invention may further contain a certain amount of opioid analgesics.
[0135] Opioid analgesics can be selected from the group consisting of: alfentanil, allylprodine, alfaprodine, analdine, apomorphine, apocodeine, benzylmorphine, benzotriamide, bufentanil, buprenorphine, butorphanol, carfentanil, morphine, codeine, cyclopolychlorinated biphenyls, cyprenorphine, dihydrodesomorphine, dezocine, diampramide, dihydrocodeine, dimesadol, dimepanol, dimethylthiambutene, dioxyphenylbutyric acid, dipipanone, eptazocine, ethylmethylthiambutene, ethylmorphine, etonirazine , fentanyl, heroin, hydrocodone, hydroxymethylmorphine, hydromorphone hydroxy, ketobemidone, isomethadone, levorphanol, levorphanol, levofenmorphan, rofentanil, pethidine, meptazocine, methadone, methylmorphine, methoprene, mirfentanil, morphine, morphine-6-glucuronide, myrophine, nalbuphine, papaverine, nicotinamide, norlevorphanol, normethadone, nalorphine, orphanin / orphanin FQ (N / OFQ), normorphine, norpipanone , hydroxymethylfentanyl, opium, oxycodone, oxydihydromorphone, opium base, pentozocin, phenoxetine, phenoxymorphone, phenoxymorphone, phenazocine, phenperidine, oxydihydromorphone, fenoxetine, primidone, proheptazine, dimethoate, profadol, propiridine, propiram, propoxyphene, remifentanil, sufentanil, tapentadol, tramadol, trefentanil, tolidine, and nalbuphine; any phenanthroline, morphinan, phenylmorphine, methadone, or phenanthroline that has agonist activity at opioid receptors any opioid substance with the same pentacyclic nucleus as nalmefene, naltrexone, buprenorphine, levorphanol, meptazocine, pentazocine and dezocine that has agonist activity on opioid receptors; any fentanyl analogue, precursor, derivative or its medically acceptable salt and mixtures thereof in racemic or enantiomeric form that has opioid receptor activity.
[0136] The following examples are provided to help understand the present invention, but should not be construed as limiting the present invention. Those skilled in the art will appreciate that variations in the specific embodiments and scope of application are possible based on the principles of the present invention. This specification should not be construed as limiting the present invention, and any variations based on the principles of the present invention are within the scope of protection of the present invention.
[0137] The following is a detailed experimental and example section of the present invention.
[0138] The following experiments will reveal some physical and chemical properties related to the solubility, formulation, compatibility and stability of the compound of formula I (Compound A) developed by the applicant. The applicant hereby declares that the rights to the following experimental data belong to the applicant.
[0139] The compound of formula I (Compound A) has the following structure:
[0140] 1. Study on the solubility and solution stability of Compound A (API)
[0141] 1.1 Investigation of the solubility of compound A in different solvents
[0142] The solubility of compound A in single solvent water, acid and alkali aqueous solutions, isopropanol, and methanol was investigated. The test results are shown in Table 1.
[0143] Table 1: Solubility of Compound A at 25°C
[0144] The above investigation results show that compound A has extremely low solubility in water and acid-base aqueous solutions, so it is chosen to be dissolved in a non-aqueous solvent to screen out a better solvent or co-solvent.
[0145] In order to increase the concentration of the API in the injection solution, the solubility of the API in a single excipient was investigated to screen for a better solvent, cosolvent, or solubilizer. The solubility test of Compound A in a single solvent was conducted as follows:
[0146] In each solvent, a specific amount of API (compound of Formula I) was added to the solution at 25°C, followed by stirring. Dissolution of the API in the solvent was observed. If complete, further API was added until a supersaturated solution was obtained. Samples were then taken and filtered every 2 hours for content determination. The solubility of each solvent at 25°C is shown in Table 2.
[0147] Table 2: Solubility data of compound A in a single solvent at 25°C
[0148] From the above data, it can be seen that compound A has the highest solubility in N,N-dimethylacetamide, exceeding 200 mg / ml, its solubility in polyoxyethylene (35) castor oil is about 20 mg / ml, and its solubility in polyethylene glycol 400 is slightly higher than that in anhydrous ethanol.
[0149] When designing an injection formulation, appropriate excipients must be added. These excipients should not affect the drug's efficacy, interfere with testing, or cause toxicity or significant irritation at concentrations sufficient to identify optimal solvents, cosolvents, or solubilizers. The solubility of Compound A in various excipients was investigated to identify the optimal solvent, cosolvent, or solubilizer.
[0150] Given that Compound A and Compound AST-3424 are structurally similar, both are nitrobenzyl derivatives, and both are linked to an aziridine-structured DNA alkylating agent that can effectively kill tumor cells. Furthermore, both can target and treat tumor tissues or cells that overexpress aldehyde-keto reductase 1C3 (AKR1C3), releasing the aziridine-structured DNA alkylating agent in tumor tissues or cells that overexpress AKR1C3 enzymes to kill tumor tissues or cells. Therefore, based on the same formulation formulation development approach, the inventors designed and screened an injection formulation similar to Compound AST-3424 (the preferred formulation for AST-3424: 10 mg / ml Compound AST-3424 + 75% ethanol + 25% propylene glycol) for use in formulation research on Compound A.
[0151] In addition to the solvent used in the formulation of the reference compound AST-3424, anhydrous ethanol is used as a commonly used and relatively safe non-aqueous solvent injection excipient. In the formulation of the developed product, N,N-dimethylacetamide (DMA) or polyoxyethylene (35) castor oil (ELP) is considered to improve solubility and enhance process convenience. The formulation composition and solubility test results of different excipients for Compound A are shown in Table 3.
[0152] Table 3: Solubility of Compound A in different excipients and experimental phenomena before and after treatment
[0153] Note: F1 is the group that only added anhydrous ethanol, and the other groups added other excipients / solvents on the basis of anhydrous ethanol, among which F2 is the propylene glycol group, F3 is the glycerol group, and F4 is the DMA group.
[0154] According to the formulation design for compound AST-3424, the volume ratio of ethanol to propylene glycol is 3:1. For a 30ml formulation solution containing 300mg of Compound A, the amount of propylene glycol used (approximately 7.8g) is between the amounts used in formulations F2-1 and F2-2. The above experimental observations indicate that Compound A cannot be completely dissolved according to the formulation design for compound AST-3424. Therefore, the formulation design for the compound of Formula I (Compound A) based on the formulation for compound AST-3424 is not feasible. The inventors need to develop alternative formulations for the formulation of Compound A.
[0155] The above formula was processed to obtain the processed formula. The phenomena before and after the treatment indicate that the surfactant polyoxyethylene (35) castor oil (ELP) and the cosolvent N,N-dimethylacetamide (DMA) facilitate the dissolution of the API. Subsequent research will be conducted using anhydrous ethanol and the cosolvent DMA. Since surfactants can increase the solubility of the API in anhydrous ethanol, preliminary research was conducted using different surfactants.
[0156] 1.2 Stability study of compound A in different solvent systems
[0157] The specific prescription information of the above-mentioned processed prescriptions F1 to F4 is as follows ("p": the corresponding prescription after adding ELP to the prescription in Table 3):
[0158] F1p: 300 mg API, 7.5 g ELP, anhydrous ethanol added to 30 ml;
[0159] F2-1p: 3 g propylene glycol, 300 mg API, 7.5 g ELP, and anhydrous ethanol to 30 ml;
[0160] F2-2p: 9 g propylene glycol, 300 mg API, 7.5 g ELP, and anhydrous ethanol to 30 ml;
[0161] F3-1p: 1.5 g glycerol, 300 mg API, 7.5 g ELP, and anhydrous ethanol to 30 ml;
[0162] F3-2p: 4.5 g glycerol, 300 mg API, 7.5 g ELP, and anhydrous ethanol to 30 ml;
[0163] F4-1: 3 g DMA, 300 mg API, add anhydrous ethanol to 30 ml;
[0164] F4-2: 9 g DMA, 300 mg API, add anhydrous ethanol to 30 ml;
[0165] F4-3: 15 g DMA, 300 mg API, add anhydrous ethanol to 30 ml.
[0166] The stability of compound A in the above formulation was investigated. At predetermined time points (0 days, 5 days, and 10 days), 1 ml of sample was taken for HPLC analysis, and its content, total impurities, and moisture data were detected respectively. The different investigation conditions and experimental results are shown in Table 4.
[0167] Table 4: Stability of Compound A in different formulation excipients at 2-8°C
[0168] Note: NA means no placement conditions were involved on day 0.
[0169] The above data show that the content, total impurities and moisture content of compound A are relatively stable when placed at 2-8°C for 10 days in each solvent system.
[0170] II. Formulation Design, Preparation and Stability Study of Compound A Injection
[0171] Based on the properties of Compound A revealed by the above solubility and solution stability studies, further formulation design, preparation and stability studies were carried out.
[0172] Compound A injection has extremely poor solubility in aqueous solvents and is composed of non-aqueous solvents. It needs to be diluted and used in combination in clinical practice. Therefore, the stability of the combination is studied simultaneously during the prescription development stage. The appearance and osmotic pressure of the solution after combination are examined to preliminarily confirm the appropriate prescription.
[0173] 2.1 Study on different surfactants, formulation composition and stability
[0174] It can be seen from the surfactant ELP used in the above experiment that surfactants with certain properties can enhance the solubility of compound A in anhydrous ethanol. The formulation composition and stability of different surfactants are now investigated. The experimental process and results are shown in Table 5.
[0175] Table 5: Investigation of different surfactants, formulation compositions and stability results
[0176] Note: HS15: relative density (Chinese Pharmacopoeia 2015 edition, Part IV, General Rules 0601) is 1.06-1.09; ELP: relative density (Chinese Pharmacopoeia 2015 edition, Part IV, General Rules 0601) is 1.05-1.06.
[0177] The above data demonstrate that Formulation F5 is essentially identical to Formulation F1. The API completely dissolved in both solvent systems, resulting in clear solutions. The API purity remained stable under the various temperatures examined. Using different surfactants (Tween 80, HS15, ELP, PEG400) also enhanced the API's solubility in anhydrous ethanol.
[0178] 2.2 Prescription design and preliminary compatibility stability study
[0179] According to the different formulations in Table 6 below, different concentrated injections of Compound A were prepared. Different compatibility media (0.9% sodium chloride injection, water for injection, 5% glucose injection) were then used to prepare different compatible solutions. The appearance, osmotic pressure, and pH value of the compatible solutions were then tested. The results of the compatibility stability study are shown in Table 7.
[0180] Table 6: Composition of different formulations of Compound A concentrated injection
[0181] Table 7: Compatibility stability test results of Compound A injection
[0182] From the preliminary research results of the above table, we can see that:
[0183] ① Reducing the proportion of ELP will increase the osmotic pressure;
[0184] ②After the sample with 20 mg / ml was mixed, the solution was mostly turbid, while after the sample with 10 mg / ml was mixed, the solution was mostly clear.
[0185] ③From the data of prescriptions F14, F15, F16, F17 and F18, it can be seen that there is no obvious difference in appearance and osmotic pressure after combination.
[0186] ④ For prescriptions F10-F13, after subsequent dilution and dissolution with 5% glucose injection as a compatibility medium, the appearance of the solution after compatibility is clear.
[0187] 2.3 Prescription screening and optimization
[0188] Based on the compatibility of different excipients for injection preparations, the solubility of Compound A, the safety of DMA for injection preparations, the prevalence of excipients in injection preparations, and the need to reduce preparation time during production, the five concentrated injection formulations listed in Table 8 below were selected for investigation. The data on related substances, content, and moisture content were examined under various conditions, including temperature, storage time, and exposure to light. The results are shown in Table 9. In addition, the compatibility stability, related substances, and content of formulation F19 were investigated. The results are shown in Tables 10, 11, and 12, respectively.
[0189] Of course, during the formulation research process, docetaxel injection and paclitaxel injection are often selected as references for comparison of the osmotic pressure of the diluents for clinical use. This serves as a reference for the clinical use of this variety. The comparison data are shown in Table 13.
[0190] Table 8: Compositions of different concentrated injections of Compound A
[0191] The stability data of different formulations of the concentrated injection of Compound A in Table 8 were investigated. The investigation conditions included whether to protect from light, different temperatures (25±2°C, 5±3°C, -20±5°C), and different storage times (0 day, 15 days, 1 month, 2 months, and 3 months). The investigation items are as follows and are recorded in Table 9:
[0192] Table 9: Stability study results of different formulations of Compound A concentrated injection - related substances, content and water content
[0193] The injection preparation of prescription F19 (2 ml: 20 mg) was prepared with different compatibility media (water for injection, 0.9% sodium chloride injection, 5% glucose injection) into compatible drug solutions with concentrations of 0.04 mg / ml and 1 mg / ml. Samples were taken at different times (0 h, 4 h, 6 h, 8 h) to measure the appearance, pH value, osmotic pressure, related substances, content (before and after filtration), etc., and the results are recorded in Table 10, Table 11 and Table 12, respectively.
[0194] The various detection items and detection methods and filtering methods of the present invention are as follows:
[0195] (1) Appearance: visual observation;
[0196] (2) pH value: Take 1 ml of this product and dilute it to 20 ml with 0.9% sodium chloride solution. <0631> First method inspection;
[0197] (3) Osmotic pressure: dew point osmometer;
[0198] (4) Determination of related substances and content: HPLC was used for detection. The detection conditions and parameters were similar to those for AST-3424. See the relevant section in patent publication WO2021 / 008520, corresponding to paragraphs 133-138 of CN112469394B. The related substances were determined using the integrated area normalization method, and the content was quantified using the external standard method.
[0199] Table 10: Compatibility stability results of formulation F19 - appearance, pH, osmotic pressure
[0200] Table 11: Compatibility Stability Study Results of Prescription F19 - Related Substances
[0201] Table 12: Compatibility stability test results of prescription F19 - content (%)
[0202] Table 13: Osmotic pressure of combined solutions of docetaxel injection and paclitaxel injection
[0203] Based on the above prescription optimization data, the following conclusions can be drawn:
[0204] ① According to the stability data of different formulations in Table 9, the content and related substance data of the five formulations F19-F23 have similar change trends, and the samples stored at -20±5℃ are relatively stable.
[0205] ② The osmotic pressure of Formula F19 when combined with 0.9% Sodium Chloride Injection and 5% Dextrose Injection was similar to that of the marketed solutions of Docetaxel Injection and Paclitaxel Injection. The osmotic pressure of Water for Injection was lower when combined with Water for Injection and was not subsequently evaluated as a compatibility medium.
[0206] ③ The solution after 0.9% sodium chloride injection and 5% glucose injection are mixed has opalescence. The content of the sample before and after filtration was tested, and it was found that the content fluctuation of the solution of 0.9% sodium chloride injection and 5% glucose injection before and after filtration was <2%, indicating that the opalescence after compound A is mixed with 0.9% sodium chloride injection and 5% glucose injection is not caused by incomplete dissolution of the product and does not affect its use.
[0207] 2.4 Compatibility stability study
[0208] Based on the established formula F19, the injection was prepared using raw and excipients of the same quality as those used in GMP production, and a compatibility stability study was conducted. Preliminary compatibility stability results showed a rapid increase in the concentration of related substances in the solution at room temperature after compatibility. Based on the physical and chemical properties of the API, the pH of the compatibility solvent was investigated. The pH of 5% glucose injection and 0.9% sodium chloride injection were first adjusted to 7.0 and 8.0, respectively, using 5% sodium bicarbonate injection. Compatibility stability studies were then conducted using these solutions.
[0209] The compatibility stability results are shown in Table 14.
[0210] Table 14: Compatibility stability results - appearance, pH, osmotic pressure, related substances
[0211] As can be seen from the data in Table 14, the pH values of the solutions of the three groups of compatibility, namely 0.9% sodium chloride injection (pH 8.0), 5% glucose injection (pH 7.0), and 5% glucose injection (pH 8.0), were greater than 7.0. The related substances were relatively stable after being placed at room temperature for 8 hours. The pH value and osmotic pressure of the solutions after compatibility met the injection requirements. The compatibility stability of prescription F19 (20 mg compound A + 0.1 g DMA + 0.8 g ELP + ethanol to 2 ml) met the injection requirements.
[0212] 3. Experimental study on factors affecting compound A injection
[0213] 3.1 Influencing factors test
[0214] Compound A injection (2 mL: 20 mg, prescription F19) was prepared, placed and processed according to the test conditions in Table 15 below, and tested according to the sampling time and test items in Table 16 below. The test items under high temperature (25°C ± 2°C) storage, light (without outer packaging), and light (with packaging) conditions were recorded in Tables 17, 18, and 19. Among them, the T0 data represents the simultaneous testing of the sample stored at -20°C for 5 days.
[0215] Table 15: Test conditions for influencing factors
[0216] Table 16: Sampling time and test items for influencing factors test
[0217] A = properties, moisture, pH value, visible foreign matter, content, and related substances.
[0218] Table 17: Test results of factors affecting high temperature (25°C ± 2°C) storage
[0219] Table 18: Test results of factors affecting light (without outer packaging)
[0220] Table 19: Test results of factors affecting light (with packaging)
[0221] The data in Tables 17, 18 and 19 above show that:
[0222] ① Appearance: The F19 injection was placed at high temperature (25℃±2℃) under light conditions for 30 days, and there was no obvious change in appearance. It was a light yellow clear liquid.
[0223] ②pH value: When the prescription F19 injection was placed at high temperature (25℃±2℃) and light conditions for 30 days, the pH value did not change significantly and was within the range of 4.5 to 7.0.
[0224] ③ Visible foreign matter: The prescription F19 injection was placed at high temperature (25℃±2℃) and light conditions for 30 days, and the visible foreign matter met the standards.
[0225] ④Total impurities: When the prescription F19 injection was placed under high temperature (25℃±2℃) conditions for 30 days, the total impurities were lower than the standard 5.0%; when placed under light (with outer packaging, pharmacopoeia illumination, 15℃) and light (without outer packaging, pharmacopoeia illumination, 15℃) conditions for 30 days, the total impurities were lower than the standard 5.0%. The growth of impurities under light exposure with and without outer packaging was the same, and the growth rate was lower than that under high temperature (25℃±2℃) conditions, both meeting the quality standards.
[0226] ⑤ Moisture: The moisture content of the F19 injection solution is no more than 0.3% when placed at high temperature (25℃±2℃) and light conditions for 30 days, which meets the standard.
[0227] ⑥Content: When the prescription F19 injection was placed under high temperature (25℃±2℃) for 30 days, the content decreased by 3.4%, which was in compliance with the quality standards; when placed under light (with outer packaging, pharmacopoeia illumination, 15℃) and light (without outer packaging, pharmacopoeia illumination, 15℃) conditions for 30 days, the content did not show obvious fluctuations, both of which were in compliance with the quality standards.
[0228] 3.2 Freeze-thaw test
[0229] Compound A injection (2 mL: 20 mg, prescription F19) was prepared and freeze-thawed according to the test conditions in Table 20 below. The freeze-thaw test results were tested according to the sampling time and test items in Table 21 below. The test items under the two freeze-thaw test conditions were recorded in Tables 22 and 23. Among them, the T0 data used the initial data of the influencing factor test in 3.1.
[0230] Experimental operation:
[0231] Freeze-Thaw Cycle 1: Prepared Compound A injection (2 mL: 20 mg) was stored at -20°C for 2 days. The sample was then transferred to a 2-8°C environment and stored for two days, which constituted one temperature cycle. Three temperature cycles were performed, and samples were analyzed after each temperature cycle. The initially prepared Compound A injection was stored at -20°C as a control.
[0232] Freeze-thaw cycle 2: Repeat the above process to perform temperature cycling from -20°C to 25°C.
[0233] Table 20: Freeze-thaw test conditions
[0234] Table 21: Freeze-thaw test sampling time and test items
[0235] A = properties, moisture, pH value, visible foreign matter, content, related substances; M = sterility, bacterial endotoxins.
[0236] Table 22: Freeze-thaw test results
[0237] Note: NA means not applicable; the T0 data of the influencing factor test are used as the initial data.
[0238] Table 23: Freeze-thaw test results
[0239] Note: NA means not applicable; the T0 data of the influencing factor test are used as the initial data.
[0240] The data in Table 22 and Table 23 above show that:
[0241] ① Appearance: The F19 injection was placed under two freeze-thaw conditions for three cycles, and there was no obvious change in appearance, and it was a light yellow clear liquid.
[0242] ② pH value: The pH value of the F19 injection solution was kept under two freeze-thaw conditions for three cycles, and there was no significant change in the pH value, which was in the range of 4.5 to 7.0.
[0243] ③ Visible foreign matter: The prescription F19 injection was placed under two freeze-thaw conditions for 3 cycles, and all visible foreign matter met the standards.
[0244] ④Total impurities: The total impurities of the F19 injection remained basically unchanged after three freeze-thaw cycles under freeze-thaw condition 1 (-20℃±5℃ for 2 days → 5℃±3℃ for 2 days). New unknown single impurities were found after three freeze-thaw cycles under freeze-thaw condition 2 (-20℃±5℃ for 2 days → 25℃±2℃ for 2 days). The new impurities did not exceed 0.1%, which met the quality standards.
[0245] ⑤ Moisture: The F19 injection solution was placed under two freeze-thaw conditions for 3 cycles, and the moisture content was no more than 0.3%, which met the standards.
[0246] ⑥ Sterility: The prescription F19 injection was placed under two freeze-thaw conditions for the third cycle, and no bacteria grew, which met the standards.
[0247] ⑦ Bacterial endotoxin: The F19 injection solution was placed under two freeze-thaw conditions for the third cycle, and the bacterial endotoxin was less than 1.2EU / mg, which met the standard.
[0248] ⑧Content: The F19 injection was frozen and thawed for three cycles under freeze-thaw conditions 1 (-20℃±5℃ for 2 days → 5℃±3℃ for 2 days) and freeze-thaw 2 (-20℃±5℃ for 2 days → 25℃±2℃ for 2 days). The content did not show obvious fluctuations and met the quality standards.
[0249] 4. Preparation process and specific examples of concentrated injection of compound A
[0250] The concentrated injection preparation of Compound A used in the above experiments can be prepared by the following process:
[0251] (1) Cleaning and sterilization of rubber stoppers
[0252] Wash, sterilize, and dry the rubber stopper before use. Steam sterilization conditions: 121°C, 30 minutes.
[0253] (2) Cleaning and sterilization of aluminum caps
[0254] Clean, sterilize, and dry the aluminum cap before use. Steam sterilization conditions: 121°C, 30 minutes.
[0255] (3) Cleaning and sterilization of vials
[0256] Clean the vial, sterilize with dry heat, and cool it before use.
[0257] (4) Weighing
[0258] Weigh the raw and auxiliary materials according to the prescribed amount.
[0259] (5) Liquid preparation and filtration
[0260] Take prescriptions F9 to F14, F19, F20, F23, etc. as an example:
[0261] Add the weighed compound A to the weighed N,N-dimethylacetamide (DMA, for injection), stir to dissolve and set aside.
[0262] Add part of anhydrous ethanol to the liquid preparation tank (temperature controlled at 15-20°C), then add weighed polyoxyethylene (35) castor oil (ELP), rinse the container with appropriate amount of anhydrous ethanol, and start stirring until the solution is visually clear.
[0263] Slowly pour the prepared solution of Compound A and N,N-dimethylacetamide (for injection) into the preparation tank. Rinse the container with an appropriate amount of anhydrous ethanol and continue stirring for 10 minutes or more until the solution is visually clear. Add more anhydrous ethanol to the total weight of the preparation and continue stirring for 20 minutes or more.
[0264] Intermediate sampling and testing. Test items: properties, pH value, moisture, density, content, bacterial endotoxins, moisture, and microbial load.
[0265] Two stages of 0.22μm sterilization-grade polytetrafluoroethylene capsule filters are connected in series, and compressed air is used to sterilize and filter the liquid medicine to the mobile liquid receiving tank at the filling station.
[0266] (6) Filling and capping
[0267] The filling volume is calculated and adjusted by weighing method. After the adjustment is qualified, filling and half-piping are started. After filling and full-piping, the intermediate product is transported to the capping room for capping.
[0268] (7) Light inspection and packaging
[0269] The intermediate products after capping are subjected to light inspection. The intermediate products that pass the light inspection are labeled, and the finished products are sampled, released for inspection, and packaged.
[0270] Taking prescriptions F9 to F14, F19, F20, F23, etc. as examples, the production process flow chart of the concentrated injection preparation of compound A (compound of formula I) is shown in Figure 1.
[0271] The present invention also provides another preparation process for Compound A injection, which is mainly used for preparing small-scale injection preparations. Compared with the above preparation process, the difference lies in the liquid preparation process, that is, the order of adding materials. The specific ideas and steps are as follows:
[0272] The concentration of Compound A injection product is 10 mg / ml, and the prescription includes 1 raw material and 3 excipients. Since the solubility of Compound A raw material decreases in the three excipients of DMA, ELP, and anhydrous ethanol in turn, the Compound A raw material (API) is first added to the prescription amount of DMA and stirred to dissolve. Compound A is completely dissolved in DMA, and then the prescription amount of ELP is added and continued to stir. Finally, the volume is fixed with anhydrous ethanol to reduce the risk of precipitation during the dissolution process of the raw material. During the operation, it was observed that the ELP and anhydrous ethanol added subsequently dissolved rapidly, and the final solution was clear and transparent.
[0273] 5. Reconstitution and Stability Study of Ready-to-Use Intravenous Injection Solution
[0274] The above studies have investigated the formulation design, stability and other properties of the concentrated injection and specific preparation examples. The following will disclose the preparation process of the ready-to-use injection and conduct stability studies.
[0275] To provide information on the compatibility of the injection of the compound of Formula I (Compound A, API) with its accompanying solutions, the short-term stability of the injection in 5% dextrose injection, a commonly used intravenous diluent, was investigated. Given the API's instability in acidic environments, the pH of the 5% dextrose injection was first adjusted to 7.4 using sodium bicarbonate solution.
[0276] 5.1 Experimental methods and procedures
[0277] Adjust the pH value of the compatibility medium: add 1.0 ml of 5% sodium bicarbonate injection to 250 ml of 5% glucose injection to adjust the pH value, mix well, and the pH value of the mixed solution is about 8.0.
[0278] Preparation of compound A complex solution: Compound A injection (2 ml: 20 mg) and pH-adjusted 5% glucose injection were used to prepare complex solutions with concentrations of 0.02 mg / ml and 1.00 mg / ml.
[0279] Preparation of 0.02 mg / ml reconstituted solution: Take 0.501 ml of Compound A injection (2 ml: 20 mg) and add it to a mixing bag containing 250 mL of 5% glucose injection (pH adjusted with 5% sodium bicarbonate injection). Ensure the mixture is well mixed by inverting the mixing bag several times before storage and sampling.
[0280] Preparation of 1.00 mg / mL reconstituted solution: Add 27.8 mL of Compound A injection (2 mL: 20 mg) to a mixing bag containing 250 mL of 5% glucose injection (pH adjusted with 5% sodium bicarbonate injection). Ensure uniform mixing by inverting the bag several times before storage and sampling.
[0281] Temperature and light conditions: All reconstituted solution samples were placed indoors under natural light conditions and stored at room temperature (25±3°C).
[0282] Sampling time and test items: 0h (before and after filtration), 2h, 4h, 8h. Appearance, solution color, solution clarity, pH value, osmotic pressure, related substances, and content.
[0283] 5.2 Experimental Results
[0284] All experimental data are recorded in Tables 24 and 25 below, summarizing the stability data of the reconstituted solutions at different concentrations.
[0285] Table 24: 0.02 mg / ml concentration compatibility solution stability test results
[0286] Table 25: 1.00 mg / ml concentration compatibility solution stability test results
[0287] Note: *: The content of 1.0 mg / ml decreased by more than 5% at 8 hours compared with that at 0 hours, so a 6-hour test was added (see Table 26). The injection products used for the combination were from the same batch.
[0288] Table 26: Results of 6-hour stability test of 1.00 mg / ml concentration compatibility solution
[0289] From the experimental data in Table 24, Table 25 and Table 26 above, it can be seen that:
[0290] The properties, clarity and content of the 0.02 mg / ml compatible solution did not change before and after filtration through a precision filtration infusion device. Within 8 hours after filtration, the properties, solution color and clarity, osmotic pressure, pH value, compound A content and related substance results of the compatible solution did not change significantly.
[0291] The properties, clarity and content of the 1.00 mg / ml compatible solution did not change before and after filtration through a precision filtration infusion device. Within 6 hours after filtration, the properties, solution color and clarity, osmotic pressure, pH value and compound A content of the compatible solution did not change significantly.
[0292] Before infusion, Prescription F19 Injection requires dilution with pH-adjusted 5% glucose injection (pre-adjust the pH by adding 1.0 ml of 5% sodium bicarbonate injection to 250 ml of 5% glucose injection). The dilution concentration should be between 0.02 mg / ml and 1 mg / ml. The solution is stable for 6 hours at room temperature under natural light. The diluted solution may exhibit opalescence due to the injection excipients. This has been shown to be stable within 6 hours after passing through a disposable precision-filtered infusion set.
[0293] VI. Study on the Chiral Stability of Compound A in Compound A Injection and Its Compatible Drug Solutions
[0294] Compound A is a racemic compound containing a chiral center. Its two isomers can be prepared by resolution from Compound A and are designated A-P1 and A-P2, respectively. During formulation and compatibility studies, the interconversion between chiral isomers may affect drug safety. Therefore, it is necessary to study the chiral stability of Compound A in its injection formulation and its compatibility solutions.
[0295] Solution preparation:
[0296] (a) According to the above-determined formula F19 and its preparation method, a concentrated injection preparation of Compound A (2 ml: 20 mg) was prepared.
[0297] (b) Prepare a 1.00 mg / ml solution of the compound solution according to the preparation method of 5.1.
[0298] Experimental methods and condition control:
[0299] The injection preparation (concentrated injection) of compound A was placed in a light-shielding, sealed, -20±5°C environment. Samples were taken at 0 months, 1 month, and 3 months, and the A-P1 and A-P2 contents were detected by the HPLC method described above to investigate stability. The results are shown in Table 27.
[0300] The 1.00 mg / ml concentration of the combined drug solution (ready-to-use injection solution) was placed at room temperature (25±2°C) under indoor natural light conditions, and samples were taken at different times of 0 h, 2 h, 4 h, 8 h, and 24 h. The A-P1 and A-P2 contents were detected by the above-mentioned HPLC method, and the chiral stability was investigated. The results are shown in Table 28.
[0301] Table 27: Chiral stability study of Compound A concentrated injection
[0302] Table 28: Investigation of chiral stability of compound A solution
[0303] The above experimental data show that compound A is chirally stable in its injection preparation and its compatible drug solution, and chiral conversion between the two isomers is almost non-existent.
Claims
1. An injection preparation, which is a solution containing a compound of the following formula I, wherein the solvent of the solution contains a C2-C8 alcohol or a liquid mixture thereof:
2. The injection preparation according to claim 1, wherein The C2-C8 alcohol is a monohydric alcohol or a polyhydric alcohol, preferably a monohydric alcohol, and more preferably ethanol.
3. The injection preparation according to claim 1, wherein the solvent of the solution further contains a nonionic surfactant as a solubilizing agent.
4. The injection preparation according to claim 3, wherein: The nonionic surfactant is selected from polyethylene glycols, hydroxystearate esters, polyoxyethylene alkyl ethers, Tweens, Spans or polyoxyethylene castor oils, The polyethylene glycols include polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, and polyethylene glycol 800; The hydroxystearate esters include 15-hydroxystearate polyethylene glycol ester and 12-hydroxystearate polyethylene glycol ester; The alkyl group in the polyoxyethylene alkyl ether includes lauryl ether alkyl, oleyl ether alkyl, stearyl alcohol alkyl and hexadecyl; The Tween class includes Tween 20, Tween 40, Tween 60, and Tween 80; The Span category includes Span 20, Span 40, Span 60, and Span 80; The polyoxyethylene castor oils include polyoxyethylene castor oil and polyoxyethylene hydrogenated castor oil.
5. The injection preparation according to claim 1, wherein The solvent also contains one or more of polyoxyethylene (35) castor oil, 15-hydroxystearate polyethylene glycol, polyethylene glycol 400, and Tween 80.
6. The injection preparation according to claim 3, wherein the volume ratio of the nonionic surfactant to the C2-C8 alcohol in the solvent of the solution is 1:(1-4).
7. The injection preparation according to claim 1, wherein the solvent of the solution further contains an organic solvent with a solubilizing effect.
8. The injection preparation according to claim 7, wherein the organic solvent with a solubilizing effect is selected from ethylenediamine, N,N-dimethylacetamide, N,N-dimethylformamide or polyvinylpyrrolidone, preferably N,N-dimethylacetamide.
9. The injection preparation according to claim 7, wherein the mass ratio of the organic solvent with solubilizing effect to the compound of formula I in claim 1 is (10-50):
1.
10. The injection preparation according to claim 1, wherein the solvent of the solution further contains a nonionic surfactant as a solubilizer and an organic solvent for a solubilizing effect.
11. The injection preparation according to claim 10, wherein: The nonionic surfactant is selected from polyoxyethylene (35) castor oil, and the organic solvent with solubilizing effect is selected from N,N-dimethylacetamide.
12. The injection preparation according to claim 10, wherein the mass ratio of the nonionic surfactant in the solvent of the solution to the compound of formula I in claim 1 is (0-90):1, preferably (5-50):1, more preferably (15-40):1, more preferably (20-40):1, and further preferably (25-40):1; or The mass ratio of the organic solvent with solubilizing effect to the compound of formula I in claim 1 in the solvent of the solution is (0-100):1, preferably (1-50):1, more preferably (5-25):1, and further preferably (5-10):
1.
13. The injection preparation according to any one of claims 1 to 12, wherein: The content of the compound of formula I is 0.1-200 mg / ml, preferably 1-100 mg / ml, and more preferably 10-20 mg / ml.
14. An injection preparation comprising the compound of formula I according to claim 1, N,N-dimethylacetamide, polyoxyethylene (35) castor oil and ethanol.
15. An injection preparation, which is composed of a compound of the following formula I, N,N-dimethylacetamide, polyoxyethylene (35) castor oil and ethanol:
16. The injection preparation according to claim 14 or 15, wherein: The content of the compound of formula I is 0.1-200 mg / ml, preferably 1-100 mg / ml, more preferably 10-20 mg / ml; The mass ratio of the compound of formula I to N,N-dimethylacetamide is 1:(0-100), preferably 1:(1-50), more preferably 1:(5-25), and further preferably 1:(5-10); The mass ratio of the compound of formula I to polyoxyethylene (35) castor oil is 1:(0-90), preferably 1:(5-50), more preferably 1:(15-40), further preferably 1:(20-40), and further preferably 1:(25-40).
17. The injection preparation according to claim 15, wherein: The content of the compound of formula I is 10 mg / ml.
18. The injection preparation according to claim 17, wherein: The compound of formula I is 20 mg, the N,N-dimethylacetamide is 100 mg, and the polyoxyethylene (35) castor oil is 800 mg.
19. A unit injection preparation, which is a concentrated ethanol solution, labeled as having a volume of 2 ml, containing 20 mg of a compound of formula I, 100 mg of N,N-dimethylacetamide and 800 mg of polyoxyethylene (35) castor oil.
20. An injection preparation comprising the compound of formula I according to claim 1 and polyoxyethylene (35) castor oil.
21. An injection preparation comprising the compound of formula I according to claim 1 and N,N-dimethylacetamide.
22. An injection preparation comprising the compound of formula I according to claim 1, N,N-dimethylacetamide and polyoxyethylene (35) castor oil.
23. The injection preparation according to any one of claims 1 to 22, wherein no water is added, and the mass percentage of water is less than or equal to 1.0%, preferably less than or equal to 0.5%.
24. An injection preparation product, comprising a packaging container and an injection preparation contained in the container, wherein the injection preparation is the injection preparation according to any one of claims 1 to 23, and is filled in a light-proof glass bottle surrounded by a medium borosilicate glass tube, characterized in that: The content of the compound of formula I in the injection preparation is 0.1-200 mg / ml, preferably 1-200 mg / ml, and more preferably 10-20 mg / ml.
25. An injection preparation product, which is essentially composed of the compound of formula I according to claim 1, N,N-dimethylacetamide, polyoxyethylene (35) castor oil and ethanol, and the injection preparation is filled in a light-proof glass bottle with a volume of 2ml, 5ml or 10ml and surrounded by a medium borosilicate glass tube, characterized in that: The content of the compound of formula I in the injection preparation is 10 mg / ml, the mass ratio of the compound of formula I to N,N-dimethylacetamide is 1:5, and the mass ratio of the compound of formula I to polyoxyethylene (35) castor oil is 1:
40.
26. A method for preparing an injection preparation, comprising the following operations: adding a prescribed amount of the compound of formula I according to claim 1 to a prescribed amount of N,N-dimethylacetamide and stirring to dissolve, then adding a prescribed amount of polyoxyethylene (35) castor oil and stirring to dissolve, and finally adding ethanol to the prescribed volume for mixing and dissolving.
27. The method for preparing the injection preparation according to claim 26, characterized in that: 20 mg of the compound of formula I according to claim 1 is added to 100 mg of N,N-dimethylacetamide and stirred to dissolve, then 800 mg of polyoxyethylene (35) castor oil is added and stirred to dissolve, and finally ethanol is added to a volume of 2 ml for mixing and dissolving.
28. A method for preparing an injection preparation, comprising the following steps: Adding a prescribed amount of the compound of formula I to a prescribed amount of N,N-dimethylacetamide and stirring to dissolve, to obtain a first dissolving preparation; adding a prescribed amount of polyoxyethylene (35) castor oil to a portion of ethanol and stirring to dissolve, to obtain a second dissolving preparation; The first dissolving and preparing solution is added to the second dissolving and preparing solution, stirred until clear, and then ethanol is added to the prescribed volume to mix and dissolve.
29. A ready-to-use injection solution, prepared from water, an isotonicity adjusting agent, and the injection solution preparation according to any one of claims 1 to 23, characterized in that: The injection solution may or may not contain a pH adjuster.
30. A ready-to-use injection solution comprising water, an isotonicity adjusting agent, a compound of formula I according to claim 1, N,N-dimethylacetamide, polyoxyethylene (35) castor oil, ethanol, and a pH adjusting agent, characterized in that: The injection solution is an isotonic solution with a pH value of 6.8-10.5 and a concentration of the compound of formula I of 0.016-1.10 mg / ml.
31. The ready-to-use injection according to claim 30, wherein: The concentration of the compound of formula I is 0.020-1.00 mg / ml.
32. The ready-to-use injection according to claim 30, wherein the pH value of the injection is 7.4-8.1, preferably 7.
7.
33. The ready-to-use injection according to claim 29 or 30, wherein: The pH adjuster is selected from one or more of sodium citrate, potassium citrate, sodium acetate, potassium acetate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, disodium hydrogen phosphate, potassium phosphate, sodium phosphate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate, and potassium carbonate.
34. The ready-to-use injection according to claim 29 or 30, wherein: The isotonicity adjusting agent is selected from the group consisting of sodium chloride, glucose, sucrose, fructose, xylitol, glycerol, sorbitol, mannitol, potassium chloride, mannose, calcium chloride, magnesium chloride or mixtures thereof in anhydrous or aqueous form.
35. An injection solution for injection, comprising water, glucose as an isotonicity adjusting agent, the compound of formula I according to claim 1, N,N-dimethylacetamide, polyoxyethylene (35) castor oil, ethanol and sodium bicarbonate as a pH adjusting agent, characterized in that: The injection is an isotonic solution with a pH value of 7.4, a concentration of the compound of formula I of 0.016-1.10 mg / ml, preferably 0.020-1.00 mg / ml, and a glucose content of 4.5-5.0% by mass.
36. The injection according to claim 35, wherein The mass ratio of the compound of formula I to N,N-dimethylacetamide is 1:5, and the mass ratio of the compound of formula I to polyoxyethylene (35) castor oil is 1:
40.
37. A method for preparing a ready-to-use injection solution, comprising the following steps: An appropriate amount of sodium bicarbonate solution containing a pH regulator is added to 5% glucose injection to obtain a mixed solution, so that the pH value of the mixed solution is 7.7-8.1; then the injection preparation according to any one of claims 1 to 23 or the injection preparation in the injection preparation product according to claim 24 or 25 is added to the above-mentioned mixed solution for mixing and dissolving.
38. The method for preparing an injection for injection according to claim 37, wherein: The mixed solution is obtained by adding 1 volume of 5% sodium bicarbonate injection into 250 volumes of 5% glucose injection.
Citation Information
Patent Citations
Stable AST-3424 injection preparation and preparation method
CN112469394A
Fluorine-containing compound and Anti-cancer medical use thereof
WO2020228685A9
Stable AST-3424 injection preparation and preparation method
WO2021008520A1
Stable AST-3424 injection preparation and preparation method
CN112220742A
Stable AST-3424 injection formulation and preparation method
CN112469394B
Cited By
Method for treating cancer and tumor patients by combining AKR1c3 enzyme-activated compound and immune checkpoint inhibitor
WO2026130539A1
